Close Menu

NEW YORK (GenomeWeb) – Taking stock of Myriad Genetics pipeline and recent stock performance, Cowen and Co. analyst Doug Schenkel today upgraded the company’s stock to an Outperform rating from a previous Market Perform rating.

"In our base case, we see a path to low-single digit to mid-single digit growth supporting multiple expansion and 15 percent to 20 percent upside from current levels without broader GeneSight reimbursement," Schenkel wrote in a note to investors. "The risk/reward is attractive."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.